Tuesday, November 09, 2010 3:46:21 PM
Monday, November 08, 2010
HALIFAX, NOVA SCOTIA--(Marketwire - Nov. 8, 2010) - Immunovaccine Inc. (TSX VENTURE:IMV) today announced positive results of a preclinical study testing the efficacy of combining CEL-2000, CEL-SCI's rheumatoid arthritis (RA) vaccine antigen, and DepoVax™, Immunovaccine's vaccine enhancement and delivery platform. The study results showed the "CEL-2000-DepoVax" combination considerably lessened the symptoms and slowed the progression of RA in the animal model with a single dose. The two companies will continue their research efforts to further optimize the CEL-2000-DepoVax vaccine combination for possible testing in future Phase I clinical trials.
The DepoVax vaccine delivery technology is amenable to manufacturing and scale up in a GMP setting, providing the potential for quicker clinical development.
"We are extremely pleased that CEL-2000, when delivered in our platform, proved efficacious with as little as one dose," said Dr. Marc Mansour, Immunovaccine's Vice President of Research and Development. "These results provide further validation of the broad potential of our DepoVax vaccine delivery technology."
The study demonstrated that the CEL-2000 formulated in DepoVax vaccine effectively slowed the progression of RA and induced a statistically significant reduction in Arthritic Index (AI) score compared to the untreated control group. An RA vaccine that provides broad protection against rheumatoid arthritis is expected to be better received than current therapies that address the symptoms associated with RA.
The results of this research collaboration were presented today at the annual GTCBio conference in Washington, D.C.
CEL-2000 is able to block the inflammatory process earlier and in an antigen-specific manner. Studies have shown that CEL-2000 inhibits the tumor necrosis factor alpha (TNF-alpha). The TNF-alpha is an important therapeutic target because it is a pro-inflammatory cytokine or regulatory protein found in abundance in RA tissue. By targeting the TNF-alpha there is a significant reduction in inflammatory activity.
CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is Multikine. In Phase II clinical trials Multikine was shown to be safe and well tolerated, and to improve the patients' overall survival by 33 percent at a median of three and a half years following surgery.
CEL-SCI is also developing an immunotherapy (LEAPS-H1N1-DC) to treat H1N1 hospitalized patients and a vaccine (CEL-2000) for Rheumatoid Arthritis using its LEAPS technology platform. The LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu as CEL-SCI scientists are very concerned about the creation of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu. This investigational treatment is being tested in a clinical study at Johns Hopkins University. The Company has operations in Vienna, Virginia, and near Baltimore, Maryland. www.cel-sci.com
About DepoVax™
Immunovaccine's DepoVax platform is a lipid depot-based vaccine delivery and enhancement technology. This patented combination is a breakthrough in vaccine development because it raises unusually strong and long-lasting cellular or humoral immune responses that allow a reduction in the number of doses required for efficacy and earlier onset of protection.
Immunovaccine Inc. (TSX VENTURE:IMV) is a clinical stage vaccine development company focused on the commercialization of its patented DepoVax™ vaccine delivery technology and product candidates.. www.imvaccine.com
Recent CVM News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/01/2024 01:13:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/01/2024 01:05:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/01/2024 12:58:09 PM
- CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer • Business Wire • 10/01/2024 10:00:00 AM
- CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation • Business Wire • 09/16/2024 11:30:00 AM
- CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress • Business Wire • 09/10/2024 01:32:00 PM
- The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance • Business Wire • 09/04/2024 01:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/30/2024 08:32:13 PM
- CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results • Business Wire • 08/15/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:27:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2024 09:16:11 PM
- CEL-SCI Announces Closing of $10.8 Million Offering • Business Wire • 07/29/2024 08:05:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/29/2024 11:00:58 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/26/2024 09:27:40 PM
- CEL-SCI Announces Pricing of $10.8 Million Offering • Business Wire • 07/26/2024 03:52:00 PM
- CEL-SCI’s Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results • Business Wire • 07/26/2024 12:23:00 PM
- CEL-SCI Appoints Robert Watson as Chairperson of the Board • Business Wire • 07/08/2024 01:15:00 PM
- CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population • Business Wire • 06/18/2024 12:00:00 PM
- Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor • Business Wire • 06/06/2024 11:00:00 AM
- CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results • Business Wire • 05/16/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:17:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 01:04:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/09/2024 05:07:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/09/2024 01:19:04 PM
- CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer • Business Wire • 05/08/2024 01:00:00 PM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM
Unitronix Corp Unveils Cryptocurrency Investment Portfolio Strategy • UTRX • Oct 2, 2024 8:40 AM
Integrated Ventures, Inc Reports Total 2024 Revenues Of $5,863,935 vs $3,862,849 for 2023. • INTV • Oct 1, 2024 9:00 AM
Nightfood Signs Letter of Intent to Acquire Los Angeles Cooking School, Integrating Automation and Robotics with World-Class Culinary Training • NGTF • Oct 1, 2024 8:30 AM
ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • COOP • Oct 1, 2024 7:00 AM
Element79 Gold Corp secures loi for launching tailings reprocessing business in Arequipa, Peru • ELMGF • Oct 1, 2024 6:38 AM